Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022290 | 0.93 | GRM2 (0.49) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2022488 | 0.86 | GRM2 (0.51) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2028589 | 0.84 | GRM2 (0.53) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2025780 | 0.83 | GRM2 (0.41) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2023270 | 0.83 | GRM2 (0.41) | GRM2ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2025534 | 0.82 | GRM2 (0.62) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2028720 | 0.81 | GRM2 (0.53) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2023956 | 0.81 | GRM2 (0.47) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2023207 | 0.80 | EGLN1 (0.38) | GRM2MCHR1 | |
| SCHEMBL2021196 | 0.79 | P2RX7 (0.36) | GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885GRIN2B 16/4885ALDH1A1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.